Non-Comparative Study of Fluconazole in Patients With Serious Mycoses and Who Cannot Be Treated With Conventional Antifungal Therapy

NCT00002038

Last updated date
Study Location
Pfizer Central Research
Groton, Connecticut, 06340, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Candidiasis, Mycoses, HIV Infections
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


Co-existing Condition:


A patient will be excluded if he/she has previously had an unacceptable adverse effect due
to fluconazole.


A patient will be excluded if he/she has previously had an unacceptable adverse effect due
to fluconazole.


AMENDED:


- 900207 Open only to unapproved indications and/or age ranges.


- Original design:


- Patients with clinically established serious or life-threatening systemic fungal
disease will be considered if conventional fungal therapy is not an acceptable
alternative. Unacceptability of conventional therapy is defined as:


- Failure of conventional therapy to control or eradicate infection after appropriate
trial(s) of generally accepted regimen(s).


- Serious and unacceptable untoward reaction(s) to conventional antifungal therapy.


- OR A major contraindication to the use of conventional antifungal therapy.


- The patient must be ineligible or have no access to other established fluconazole
investigational protocols. The final judgment of patient acceptability for inclusion
lies with the Pfizer Clinical Monitor.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Candidiasis, Mycoses, HIV InfectionsRandomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081)
NCT00000676
  1. Palo Alto, California
  2. San Diego, California
  3. San Francisco, California
  4. Miami, Florida
  5. Chicago, Illinois
  6. Chicago, Illinois
  7. Indianapolis, Indiana
  8. New Orleans, Louisiana
  9. Baltimore, Maryland
  10. Boston, Massachusetts
  11. Boston, Massachusetts
  12. Boston, Massachusetts
  13. Minneapolis, Minnesota
  14. St. Louis, Missouri
  15. Buffalo, New York
  16. New York, New York
  17. New York, New York
  18. Rochester, New York
  19. Chapel Hill, North Carolina
  20. Durham, North Carolina
  21. Cincinnati, Ohio
  22. Cleveland, Ohio
  23. Columbus, Ohio
  24. Pittsburgh, Pennsylvania
  25. Seattle, Washington
  26. Mbeya,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Candidiasis, Mycoses, HIV InfectionsNon-Comparative Study of Fluconazole in Patients With Serious Mycoses and Who Cannot Be Treated With Conventional Antifungal Therapy
NCT00002038
  1. Groton, Connecticut
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Non-Comparative Study of Fluconazole in Patients With Serious Mycoses and Who Cannot Be Treated With Conventional Antifungal Therapy
Official Title  ICMJE Non-Comparative Study of Fluconazole in Patients With Serious Mycoses and Who Cannot Be Treated With Conventional Antifungal Therapy
Brief Summary The primary purpose of this protocol is to provide fluconazole for the treatment of individual patients who require therapy for serious or life-threatening systemic fungal infection, who have failed on conventional antifungal therapy or have had unacceptable reactions to conventional antifungal therapy, and who are ineligible for other established fluconazole clinical trial protocols.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Primary Purpose: Treatment
Condition  ICMJE
  • Candidiasis
  • Mycoses
  • HIV Infections
Intervention  ICMJE Drug: Fluconazole
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE Not Provided
Original Enrollment  ICMJE Not Provided
Study Completion Date  ICMJE Not Provided
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Exclusion Criteria

Co-existing Condition:

A patient will be excluded if he/she has previously had an unacceptable adverse effect due to fluconazole.

A patient will be excluded if he/she has previously had an unacceptable adverse effect due to fluconazole.

AMENDED:

  • 900207 Open only to unapproved indications and/or age ranges.
  • Original design:
  • Patients with clinically established serious or life-threatening systemic fungal disease will be considered if conventional fungal therapy is not an acceptable alternative. Unacceptability of conventional therapy is defined as:
  • Failure of conventional therapy to control or eradicate infection after appropriate trial(s) of generally accepted regimen(s).
  • Serious and unacceptable untoward reaction(s) to conventional antifungal therapy.
  • OR A major contraindication to the use of conventional antifungal therapy.
  • The patient must be ineligible or have no access to other established fluconazole investigational protocols. The final judgment of patient acceptability for inclusion lies with the Pfizer Clinical Monitor.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00002038
Other Study ID Numbers  ICMJE 012C
056-152
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account NIH AIDS Clinical Trials Information Service
Verification Date June 1996

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP